Ozempic and Cannabis Addiction: Surprising Link

For years, medications like Ozempic and Wegovy—known scientifically as GLP-1 receptor agonists—have been celebrated for helping people manage diabetes and lose weight.  But a growing body of research now suggests these drugs might also influence something unexpected: the brain’s relationship with addictive substances, including cannabis.

It is important to remember that, while cannabis may offer many tremendous benefits to specific users, some suffer from addiction and would be better served by not consuming the plant.  With that in mind, a notable new review¹ published in the Journal of the Endocrine Society by researchers from the U.S. National Institutes of Health explores how GLP-1 drugs interact with various substance use disorders.  While most of the evidence centers on alcohol, nicotine, and opioids, the paper highlights several intriguing findings about how these drugs might also affect cannabis use and the body’s endocannabinoid system.

The Endocannabinoid System and Appetite

Cannabis interacts with a built-in network in the body called the endocannabinoid system, which helps regulate mood, appetite, and reward.  When someone uses cannabis, compounds like THC activate CB1 receptors in the brain—these are the same receptors involved in signaling hunger and pleasure after eating.

Interestingly, GLP-1 (glucagon-like peptide-1) hormones also play a significant in controlling appetite and satiety.  When GLP-1 levels rise after a meal, they tell the brain you’re full and help regulate blood sugar.  Drugs that mimic this hormone, such as semaglutide (Ozempic, Wegovy), prolong that effect, reducing hunger and food cravings.

Because both GLP-1 and endocannabinoid signaling influence the brain’s reward and appetite pathways, scientists have begun to wonder whether manipulating one system could affect the other.

What the NIH Study Revealed About Ozempic and Cannabis Use

The NIH-backed review outlines several new and emerging links between GLP-1 drugs and cannabis use:

Swipe to scroll →

Together, these findings point toward a possible therapeutic connection—one that could open the door to new treatments for people struggling with heavy cannabis use or dependence.

How GLP-1 and Cannabis Interact in the Brain

Both GLP-1 and cannabinoids act on parts of the brain responsible for reward, stress, and motivation—particularly the ventral tegmental area (VTA) and nucleus accumbens (NAc).  These are the same regions activated by dopamine during pleasurable experiences like eating or drug use.

By dampening reward responses in these circuits, GLP-1 drugs may reduce cravings or the drive to seek substances.  In studies involving alcohol and nicotine, activating GLP-1 receptors has been shown to decrease self-administration and relapse behavior in animals.  While this hasn’t yet been proven for cannabis, early data imply that the same mechanism could apply.

Another piece of evidence comes from weight-management research.  Cannabis users often have lower body mass indices (BMIs) than non-users despite higher caloric intake—a long-standing puzzle in metabolic science.  Since GLP-1 and cannabinoid pathways both regulate energy balance, researchers believe these two systems might counteract each other in interesting ways.

Why This Discovery Matters for Cannabis Addiction Treatment

Cannabis use disorder affects millions worldwide, yet there are no FDA-approved medications to treat it.  Current therapies rely mostly on counseling, behavioral support, and gradual reduction strategies.  If GLP-1 drugs could help reduce cravings or interrupt the reward cycle tied to cannabis use, it would represent a significant breakthrough in addiction medicine.

There’s also an important public-health overlap.  Many people prescribed GLP-1 drugs already use cannabis—either recreationally or for medical reasons such as chronic pain, anxiety, or sleep.  Understanding how these drugs interact is crucial for patient safety and for tailoring guidance on side effects, appetite changes, and mood shifts.

What Comes Next

Researchers are quick to caution that the evidence is preliminary.  The current data come mostly from observational studies, social-media analyses, and a handful of lab experiments.  There are no large clinical trials yet testing GLP-1 drugs specifically for cannabis addiction.

A major reason this discovery matters is that GLP-1 drugs offer a non-psychoactive approach to addiction treatment. Instead ofectly targeting brain receptors in the way that cannabis does, these drugs work by modulating the body’s underlying hormonal and metabolic systems that influence reward, satiety, and craving.

Still, the overlap between these systems offers a promising path forward.  As scientists continue to explore GLP-1 agonists for alcohol, nicotine, and opioid use disorders, future trials could include cannabis as well.  If successful, this class of medication could represent a new kind of pharmacotherapy—one that targets both metabolic health and addictive behavior through shared brain chemistry.

For now, experts recommend that anyone using both cannabis and GLP-1 drugs do so carefully and under medical supervision, since the combination may intensify nausea or alter appetite signals.

The Takeaway

GLP-1 medications like Ozempic may be doing more than curbing hunger—they might also influence how the brain responds to addictive substances, including cannabis.  While it’s far too early to call them a treatment for cannabis use disorder, early findings hint at a surprising and potentially valuable connection between the body’s metabolic and endocannabinoid systems.

As with many discoveries at the crossroads of metabolism and mental health, this line of research reminds us that our appetite, reward, and motivation systems are more deeply linked than we ever imagined.

References:

^{1. Srinivasan, N. M., Farokhnia, M., Farinelli, L. A., Ferrulli, A., & Leggio, L. (2025). GLP-1 therapeutics and their emerging in alcohol and substance use disorders: An endocrinology primer. Journal of the Endocrine Society, 9(11), bvaf141. https://doi.org/10.1210/jendso/bvaf141}